Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia

Australasian Psychiatry

Volumn 24, Issue 2, 2016, Pages 176-180

  Youssef, Daniel L ^a,b   Narayanan, Pradeep ^c   Neeraj, Gill ^a,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c TOOWOOMBA HOSPITAL   (Australia)

^d Gold Coast Health   (Australia)

Author keywords

Cardiomyopathy; Clozapine; Incidence; Myocarditis; Risk factors

Indexed keywords

CLOZAPINE; SEROTONIN UPTAKE INHIBITOR; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE FAILURE; HUMAN; INCIDENCE; LEFT VENTRICULAR DILATATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL HEALTH SERVICE; MYOCARDITIS; NEUTROPENIA; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; RISK ASSESSMENT; SIDE EFFECT; CHEMICALLY INDUCED; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CARDIOMYOPATHIES; CLOZAPINE; FEMALE; HUMANS; INCIDENCE; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; MYOCARDITIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84966545952     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856215604480     Document Type: Article

References (18)

1. Alvir JM and Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55: 137-138.
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
3. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-1845.
4. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38: 915-922.
5. Dukes MN. The importance of adverse reactions in drug regulation. Drug Saf 1990; 5: 3-6.
6. Haas SJ, Hill R, Krum H, et al. Clozapine- associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30: 47-57.
7. Tirupati S. Clozapine and heart in the Hunter region. Aust N Z J Psychiatry 2006; 40: 97.
8. La Grenade L, Graham D and Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345: 224-225.
9. Domenichetti S, Rostagno C, Pastorelli F, et al. Clozapine and cardiomyopathy. An investigation conducted in a mental health service. Ital J Psychopathol 2010; 16: 286-298.
10. Hagg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 382-388.
11. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458-465.
12. Tanner MA and Culling W. Clozapine associated dilated cardiomyopathy. Postgraduate Med J 2003; 79: 412-413.
13. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophrenia Res 2012; 141: 173-178.
14. Alpert MA and Kelly DL. Value and limitations of echocardiography in the assessment of obese patients. Echocardiography 1986; 3: 261-272.
15. Vignola PA, Bloch A, Kaplan AD, et al. Interobserver variability in echocardiography. J Clin Ultrasound 1977; 5: 238-242.
16. Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs 2007; 21: 117-127.
17. Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33: 213-217.
18. Centorrino F, Baldessarini RJ, Frankenburg FR, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153: 820-822.